Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03311009 · ClinicalTrials.gov registry record · Phase 1

A Study With GLPG1972 in Osteoarthritis Subjects

A Phase 1 study of Osteoarthritis, sponsored by Galapagos.

Completed
Registry status
Phase 1
Development phase
30
Enrollment target
1
Study location

NCT03311009: Completed Phase 1 study of Osteoarthritis, sponsored by Galapagos.

NCT03311009 is a Phase 1 study of Osteoarthritis that has completed, run by Galapagos. The registered enrollment target is 30 participants, below the 818-participant average among 135 other Osteoarthritis trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03311009, a Phase 1 study of Osteoarthritis, has completed, sponsored by Galapagos.

COMPLETED
Registry status
Phase 1
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA), administered GLPG1972 or placebo. Per cohort, 10 subjects will be randomized in a 4:1 allocation ratio to active treatment with GLPG1972 or matching placebo. In each cohort, OA subjects will be stratified for age (50- 64 years and 65-75 years) with a minimum of 2 of each sex per age group.

Primary Outcome

To assess safety and tolerability of GLPG1972 in OA patients

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG GLPG1972 cohort 1
  • DRUG GLPG1972 cohort 2
  • DRUG GLPG1972 cohort 3

Study Locations (1)

Florida

  • Covance Daytona Beach - Daytona Beach

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2017-05-15
Est. Completion 2017-10-25
Phase Phase 1
Galapagos

7 total trials

What the finished NCT03311009 record still lists

NCT03311009 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 818-participant average among 135 other Osteoarthritis trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Osteoarthritis appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT03311009 reports a single indexed study location in Florida.

Frequently Asked Questions

What is clinical trial NCT03311009 about?

NCT03311009 is a clinical study titled "A Study With GLPG1972 in Osteoarthritis Subjects". This is a randomized, double-blind, placebo-controlled, stratified, ascending dose, single center study, in three semi-sequential cohorts of 10 male and female subjects of nonchildbearing potential with Osteoarthritis (OA), administered GLPG1972 or placebo. Per cohort, 10 subjects will be randomized...

What is the current status of trial NCT03311009?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-05-15. Estimated completion is 2017-10-25.

What conditions does trial NCT03311009 study?

This clinical trial studies the following conditions: Osteoarthritis.

What interventions are being tested in trial NCT03311009?

The interventions under investigation include: Placebo (DRUG), GLPG1972 cohort 1 (DRUG), GLPG1972 cohort 2 (DRUG), GLPG1972 cohort 3 (DRUG).

Who is sponsoring clinical trial NCT03311009?

This trial is sponsored by Galapagos, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03311009 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Osteoarthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03311009's enrollment target sits among peer trials

30 128th of 135 higher than 7 of 135 other Osteoarthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Osteoarthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03311009, the US trial registry maintained by the National Library of Medicine. NCT03311009 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.